BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month
Latest product candidate reaffirms growth opportunities for hydrophilic topical delivery system
Jan 12, 2018
MENLO PARK, Calif., Jan. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present to the medical community preliminary data from the treatment of rosacea using its novel topical gel, BPX-04.
BPX-04 is the company's latest addition to its clinical pipeline. It is the second product built on the proprietary, patent-pending BioPharmX hydrophilic topical delivery system. BPX-04 reinforces the value of the unique delivery system as BioPharmX researchers explore other applications.
BioPharmX presentations will include:
- "Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study," which will be presented at the Winter Clinical Dermatology Conference – Hawaii, Jan. 12-17. The poster will show that clinically meaningful improvements were reported after just four weeks of treatment.
- "Cutaneous Tolerability of a Novel Topical Minocycline Gel for the Treatment of Rosacea," which will be presented at Maui Derm for Dermatologists 2018 conference, Jan. 28-Feb. 1. The poster will show that most subject ratings for burning, stinging, tightness and itching improved or were unchanged.
"The promise of BPX-04 continues to reinforce the value of our topical delivery system and its ability to deliver new therapies for multiple indications," said Anja Krammer, co-founder and president of BioPharmX. "These presentations allow us to fulfill the demand for information about our research and communicate results of promising topical therapies to physicians."
In addition, BioPharmX will be highlighted in discussions of emerging therapies, featuring BPX-01 for acne and BPX-04 for rosacea:
Winter Clinical Derm Conference Hawaii, Maui – January 12-17
- "What's New in Topical Therapy," a presentation by Dr. Linda Stein-Gold Jan. 14, 10:45 a.m.
- "What's New in Medicine Chest, Part 2," a presentation by Dr. Jim Del Rosso Jan. 15, 9:40a.m.
- "New Developments in Topical Therapies," a presentation by Dr.s Jim Del Rosso, Linda Stein-Gold and Joshua Zeichner Jan 16, 9:30 a.m.
- "What's New & Coming in Therapeutics," a second presentation by Dr. Del Rosso Jan. 17, 1 p.m.
MauiDerm2018, Wailea – January 28-February 1
- "Acne and Rosacea," a session moderated by Dr. Guy Webster Jan. 31, 7:30-8:45 a.m.
Oral minocycline has been widely used since the 1970s, however oral antibiotics tend to flood the body with medicine and are associated with adverse effects that range from nausea to diarrhea. There is also growing concern over the rise in antibiotic-resistant bacteria. Despite results that show minocycline produces less resistance than other tetracycline-class antibiotics (e.g. doxycycline and tetracycline) in oral form, the pharmaceutical industry has not brought to market any stable, soluble topical formulations of minocycline. BioPharmX has developed a topical gel formulation of minocycline that reaches areas of the skin, where acne, rosacea, and other conditions develop. By applying minocycline topically, systemic uptake of minocycline is reduced relative to oral delivery and thus the drug's beneficial effects are focused in the skin where P.acnes bacteria are located.
BioPharmX has successfully completed a phase 2b trial for BPX-01 and is preparing for phase 3 trials. The company is currently conducting a pilot clinical study for BPX-04 and is preparing for a phase 2 trial.
About BPX-01 and BPX-04
BPX-011 and BPX-041 are hydrophilic (non-oil-based) topical gels with fully solubilized minocycline that have been shown to penetrate the skin to deliver the antibiotic to its target. Following positive results from its previously announced phase 2b dose range study of BPX-01 in acne, BioPharmX continues with phase 3 clinical study plans for BPX-01 for the treatment of inflammatory lesions of acne and phase 2 clinical plans for BPX-04 for the treatment of rosacea.
About BioPharmX Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding strategic partnering alternatives, the safety and medical effects of BPX-04 and BPX-01, the effect BPX-04 and BPX-01 may have on the treatment of rosacea and acne, respectively, the commencement and results of future trials of BPX-04 and BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-04 and BPX-01, absence of side effects of future use of BPX-04 and BPX-01 and ability to advance BPX-04 and BPX-01 through a successful NDA submission and commercialization. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and our quarterly report on Form 10-Q for the period ended July 31, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
1 Caution: BPX-01 and BPX-04 are new drugs limited by U.S. law to investigational use.
SOURCE BioPharmX Corporation
For further information: Nina Brauer, email@example.com (650) 889-5030; OR Jim Martinez, firstname.lastname@example.org (312) 543-9026